Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis.

被引：0
|
作者：
van de Putte, BA
Rau, R
Breedveld, FC
Kalden, JR
Malaise, MG
Schattenkirchner, M
Emery, P
Burmester, GR
Zeidler, H
Moutsopoulos, HH
Compagnone, D
Kempeni, J
Kupper, H
机构：
来源：
ARTHRITIS AND RHEUMATISM | 1999年 / 42卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1977
引用
收藏
页码：S400 / S400
页数：1
相关论文
共 50 条
  • [21] FCGR2A Polymorphism and Response to Anti-TNF Treatment in Rheumatoid Arthritis.
    Avila, G.
    Tornero, Jesus
    Fernandez Nebro, Antonio
    Blanco, Francisco
    Gonzalez-Alvaro, Isidoro
    Canete, Juan D.
    Maymo, Joan
    Ballina, Javier
    Fernandez Gutierrez, Benjamin
    Olive, Alejandro
    Corominas, Hector
    Erra, Alba
    Tortosa, Rauel
    America Lopez-Lasanta, Maria
    Aterido, Adria
    Julia, Antonio
    Marsal, Sara
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S496 - S496
  • [22] Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis:: a 12 week, phase II study
    van de Putte, LBA
    Rau, R
    Breedveld, FC
    Kalden, JR
    Malaise, MG
    van Riel, PLCM
    Schattenkirchner, M
    Emery, P
    Burmester, GR
    Zeidler, H
    Moutsopoulos, HM
    Beck, K
    Kupper, H
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (12) : 1168 - 1177
  • [23] The ARMADA trial: A double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate (MTX).
    Keystone, E
    Weinblatt, M
    Furst, D
    Weisman, M
    Moreland, L
    Birbara, C
    Fischkoff, S
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S213 - S213
  • [24] Adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, improved health-related quality of life in patients with active rheumatoid arthritis despite concomitant methotrexate therapy.
    Wellborne, F
    Keystone, EC
    Kivitz, A
    Greenwald, M
    Teoh, L
    Fischkoff, S
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S518 - S518
  • [25] PHARMACOKINETICS OF GOLIMUMAB, AN ANTI-TNFα HUMAN MONOCLONAL ANTIBODY, AFTER MULTIPLE SUBCUTANEOUS OR INTRAVENOUS INJECTIONS IN SUBJECTS WITH RHEUMATOID ARTHRITIS.
    Zhuang, Y.
    Xu, Z. H.
    Frederick, B.
    de Vries, D. E.
    Zong, X.
    Ford, J. A.
    Rahman, M. U.
    Petty, K. J.
    Davis, H. M.
    Zhou, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S34 - S35
  • [26] Efficacy and safety of switching etanercept to an anti-TNF monoclonal antibody in patients with juvenile idiopathic arthritis.
    Russo, Ricardo A.
    Katsicas, Maria M.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S681 - S682
  • [27] Comparison of adalimumab (D2E7), infliximab, and etanercept in the prevention of polyarthritis in a transgenic murine model of rheumatoid arthritis.
    Kaymakcalan, Z
    Beam, C
    Kamen, R
    Abbot, JS
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S304 - S304
  • [28] Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis
    Xi Xie
    Fen Li
    Shu Li
    Jing Tian
    Jin-wei Chen
    Jin-feng Du
    Ni Mao
    Jian Chen
    Clinical Rheumatology, 2018, 37 : 13 - 23
  • [29] Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis
    Xie, Xi
    Li, Fen
    Li, Shu
    Tian, Jing
    Chen, Jin-wei
    Du, Jin-feng
    Mao, Ni
    Chen, Jian
    CLINICAL RHEUMATOLOGY, 2018, 37 (01) : 13 - 23
  • [30] Onset of efficacy of anti-TNF alfa monoclonal antibody (remicade) in rheumatoid arthritis portuguese patients
    Vilar, A
    Araújo, D
    de Queiroz, MV
    Figueiredo, G
    Vaz, L
    André, R
    Moura, A
    Porto, A
    Quintal, A
    Branco, J
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 428 - 428
12345